CoChat
Sign Up
Cited by 11,486Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchLung Cancer Research Studies

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, Thomas J., Bell, Daphne W., Sordella, Raffaella, Gurubhagavatula, Sarada, Okimoto, Ross A., Brannigan, Brian W., Harris, Patricia L., Haserlat, Sara M., Supko, Jeffrey G., Haluska, Frank G., Louis, David N., Christiani, David C., Settleman, Jeff, Haber, Daniel A.·2004·New England Journal of Medicine
DOI 10.1056/nejmoa040938
Open this paper in CoChat — free account

Abstract

BACKGROUND: Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown. METHODS: We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib. The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells. RESULTS: Somatic mutations were identified in the tyrosine kinase domain of the EGFR gene in eight of nine patients with gefitinib-responsive lung cancer, as compared with none of the seven patients with no response (P<0.001). Mutations were either small, in-frame deletions or amino acid substitutions clustered around the ATP-binding pocket of the tyrosine kinase domain. Similar mutations were detected in tumors from 2 of 25 patients with primary non-small-cell lung cancer who had not been exposed to gefitinib (8 percent). All mutations were heterozygous, and identical mutations were observed in multiple patients, suggesting an additive specific gain of function. In vitro, EGFR mutants demonstrated enhanced tyrosine kinase activity in response to epidermal growth factor and increased sensitivity to inhibition by gefitinib. CONCLUSIONS: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene, which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib. These mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor. Screening for such mutations in lung cancers may identify patients who will have a response to gefitinib.

Overview

Integrity signals

Registry

Crossref · 10.1056/nejmoa040938

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Flagged first, then by citations

Show all 31 references

Research works printed but not linked: 3

  1. Wakeling AE, 2002, Cancer Res, 62, 5749
  2. Frederick L, 2000, Cancer Res, 60, 1383
  3. Li B, 2003, Cancer Res, 63, 7443

Cited by

Sorted by citations

Items 801–900 of 1,081

Related

See all

Metadata

Authors
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., Louis, D. N., Christiani, D. C., Settleman, J., & Haber, D. A.
Affiliations
Harvard University (US)
ORCID
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2004-05-20
Volume
350
Issue
21
Pages
2129-2139
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa040938
OpenAlex
W2043696829
Cited by
11,486
References
31
Citations by year
2026: 194 · 2025: 220 · 2024: 236 · 2023: 380 · 2022: 328 · 2021: 374 · 2020: 421 · 2019: 388 · 2018: 490 · 2017: 561 · 2016: 616 · 2015: 673 · 2014: 679 · 2013: 691 · 2012: 683
FWCI
606.47
Type
journal article
Language
en
Open access
closed
Locations
  • New England Journal of Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (acceptedVersion)
Funders
  • U.S. Public Health Service (P01 95281)
  • National Cancer Institute (P30-CA0516, R01CA092824, P50CA090578)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords
non-small cell lung cancer, epidermal growth factor receptor, gefitinib, EGFR mutation, tyrosine kinase inhibitors, drug sensitivity, ATP binding site, gain-of-function mutations, tyrosine kinase activity, predictive biomarkers, targeted therapy
MeSH terms
Gefitinib, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Amino Acid Sequence, Antineoplastic Agents, Base Sequence, Carcinoma, Non-Small-Cell Lung, DNA Mutational Analysis, Epidermal Growth Factor, Female, Heterozygote, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Protein-Tyrosine Kinases, Quinazolines, Sequence Deletion, Genes, erbB-1, Drug Resistance, Neoplasm, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review